Cargando…

Viral hepatitis in 2021: The challenges remaining and how we should tackle them

Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Rebecca, Wetten, Aaron, McPherson, Stuart, Donnelly, Mhairi C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793011/
https://www.ncbi.nlm.nih.gov/pubmed/35125820
http://dx.doi.org/10.3748/wjg.v28.i1.76
_version_ 1784640503489232896
author Dunn, Rebecca
Wetten, Aaron
McPherson, Stuart
Donnelly, Mhairi C
author_facet Dunn, Rebecca
Wetten, Aaron
McPherson, Stuart
Donnelly, Mhairi C
author_sort Dunn, Rebecca
collection PubMed
description Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research.
format Online
Article
Text
id pubmed-8793011
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87930112022-02-03 Viral hepatitis in 2021: The challenges remaining and how we should tackle them Dunn, Rebecca Wetten, Aaron McPherson, Stuart Donnelly, Mhairi C World J Gastroenterol Review Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research. Baishideng Publishing Group Inc 2022-01-07 2022-01-07 /pmc/articles/PMC8793011/ /pubmed/35125820 http://dx.doi.org/10.3748/wjg.v28.i1.76 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
Dunn, Rebecca
Wetten, Aaron
McPherson, Stuart
Donnelly, Mhairi C
Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title_full Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title_fullStr Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title_full_unstemmed Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title_short Viral hepatitis in 2021: The challenges remaining and how we should tackle them
title_sort viral hepatitis in 2021: the challenges remaining and how we should tackle them
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793011/
https://www.ncbi.nlm.nih.gov/pubmed/35125820
http://dx.doi.org/10.3748/wjg.v28.i1.76
work_keys_str_mv AT dunnrebecca viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem
AT wettenaaron viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem
AT mcphersonstuart viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem
AT donnellymhairic viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem